Evolution of the Average Target: Afya Limited

Evolution of the Average Target - Afya Limited

Evolution of the Target Price: Afya Limited

Evolution of the Target Price - Afya Limited

Changes in Analyst Recommendations: Afya Limited

21ae7412ed6dbefc7e9ea386288a094.PnrfrWUJuequgJOHgbaSX5GHmjcsiFhkUH-dtjl048w.YU2t5zJ52IzdzqPhtZvrbsLuzWdI_QInM07c529BtIYOV-vMID3Wm-vo_A~ed04c67e73bbfacc430236cc21480c92
11-05 Morgan Stanley Upgrades Afya to Equalweight From Underweight, Price Target is $12.60 MT
11-03 Citigroup Upgrades Afya to Buy From Neutral, $12 Price Target MT
10-29 BofA Securities Upgrades Afya to Buy From Neutral MT
10-08 Afya Shares Rise After JPMorgan Upgrade MT
10-07 JPMorgan Upgrades Afya to Overweight From Neutral, $19 Price Target MT
02-24 BofA Securities Downgrades Afya to Neutral From Buy, Price Target is $17 MT
02-14 Afya Shares Fall After Morgan Stanley Downgrade MT
02-13 Morgan Stanley Downgrades Afya to Underweight From Equalweight, Adjusts Price Target to $16 From $17.50 MT
01-16 UBS Downgrades Afya to Neutral From Buy, Adjusts PT to $16 From $18 MT
01-08 UBS Trims Afya Price Target to $18 From $19, Maintains Buy Rating MT
01-07 JPMorgan Downgrades Afya to Neutral From Overweight, Adjusts Price Target to $22 From $24.50 MT
08/09/25 UBS Upgrades Afya to Buy From Neutral, $19 Price Target MT
08/09/25 JPMorgan Upgrades Afya to Overweight, Price Target is $24.50 MT
07/08/25 Afya Shares Rise After Morgan Stanley Upgrade MT
06/08/25 Morgan Stanley Upgrades Afya to Equalweight From Underweight, Adjusts Price Target to $17.50 From $19 MT
29/07/25 Citigroup Upgrades Afya to Neutral From Sell, Adjusts Price Target to $14 From $16 MT
12/06/25 UBS Hikes Afya Price Target to $19.50 From $17.50, Maintains Neutral Rating MT
11/03/25 Morgan Stanley Downgrades Afya to Underweight From Equal Weight, Cuts Price Target to $17 From $19 MT
05/02/25 Bradesco BBI Downgrades Afya to Underperform From Neutral, Adjusts Price Target to $14 From $17 MT
31/01/25 Citigroup Downgrades Afya to Sell From Neutral, Adjusts Price Target to $15 From $18 MT
17/12/24 UBS Cuts Price Target on Afya to $17.50 From $19.50, Keeps Neutral Rating MT
30/08/24 UBS Initiates Coverage on Afya With Neutral Rating, Sets $19.50 Price Target MT
21/06/24 Morgan Stanley Adjusts Price Target on Afya to $19 From $21, Maintains Equalweight Rating MT
27/11/23 JPMorgan Downgrades Afya to Neutral From Overweight, Adjusts Price Target to $23 From $22 MT
22/11/22 Credit Suisse Adjusts Afya's Price Target to $18 From $19, Keeps Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - -12.99%
+25.03%
+38.6%
+48.6%
+42.57%
+36.88%
+73.93%
+105.29%
Average +44.74%
Weighted average by Cap. +20.79%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
59.10BRL
Average target price
87.01BRL
Spread / Average Target
+47.22%
High Price Target
101.49BRL
Spread / Highest target
+71.71%
Low Price Target
65.26BRL
Spread / Lowest Target
+10.41%

Analyst Consensus Detail

Analyst consensus - Afya Limited

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Afya Limited
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Afya Limited